A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
The purpose of the study is to compare the efficacy of anti-COVID-19 immune globulin (human) 20% (C19-IG 20%) (2 doses) versus placebo with regard to the percentage of asymptomatic participants who remain asymptomatic, i.e., who do not develop symptomatic coronavirus disease 2019 (COVID-19) through Day 14 as per the protocol defined criteria.
Epistemonikos ID: 964ebd473be51b42fc0c25506d7ab06cc67a4c7f
First added on: Apr 20, 2021